Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.
Angélique Vienot, Dewi Vernerey, Adeline Bouard, Elodie Klajer, Stefano Kim, Christophe Tournigand, Christophe Louvet, Thierry André, Benoît Rousseau, Mylène Wespiser, Laurie Spehner, Ying A Wang, Anke Weispfenning, Emmanuelle Dochy, Christophe Borg
{"title":"Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.","authors":"Angélique Vienot, Dewi Vernerey, Adeline Bouard, Elodie Klajer, Stefano Kim, Christophe Tournigand, Christophe Louvet, Thierry André, Benoît Rousseau, Mylène Wespiser, Laurie Spehner, Ying A Wang, Anke Weispfenning, Emmanuelle Dochy, Christophe Borg","doi":"10.1158/2767-9764.CRC-24-0246","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>STC1 is a protein secreted by intratumor endothelial cells in which plasma concentrations increase in patients with chemorefractory mCRC. Based on analyses of patients with refractory mCRC in the TEXCAN and CORRECT trials, we found that STC1 plasma levels had a prognostic role for OS, with high levels associated with poor outcome. A predictive role for baseline STC1 levels was pointed out for regorafenib efficacy.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"287-294"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811826/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Significance: STC1 is a protein secreted by intratumor endothelial cells in which plasma concentrations increase in patients with chemorefractory mCRC. Based on analyses of patients with refractory mCRC in the TEXCAN and CORRECT trials, we found that STC1 plasma levels had a prognostic role for OS, with high levels associated with poor outcome. A predictive role for baseline STC1 levels was pointed out for regorafenib efficacy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
